论文部分内容阅读
目的研究90%单甲脒盐酸盐原药的致突变性。方法在活化和非活化条件下,采用小鼠淋巴瘤细胞株(L5178Y-3.7.2C)进行TK基因突变试验,分析不同剂量90%单甲脒盐酸盐原药(0.078～5.0 mg/ml)的致突变性。结果在有和无体外代谢活化系统S9时,1.25、0.625、0.313、0.156 mg/ml剂量组的90%单甲脒盐酸盐原药TK位点突变频率稍有增加,但与溶剂对照组比较,均无统计学意义(P>0.05)。结论在本体外哺乳动物细胞基因突变试验剂量范围内,未见90%单甲脒盐酸盐原药具有致突变性。
Objective To study the mutagenicity of 90% mono-formamidine hydrochloride. Methods TK gene mutation test was carried out in mouse lymphoma cell line (L5178Y-3.7.2C) under the conditions of activation and non-activation. The effects of different doses of 90% mono-formamidine hydrochloride (0.078-5.0 mg / ml) Mutagenicity. Results In the presence and absence of metabolic activation system S9, the frequency of TK mutation at the concentrations of 1.25%, 0.625%, 0.313% and 0.156 mg / ml of 90% monoamidine hydrochloride slightly increased, but compared with the solvent control group , No statistical significance (P> 0.05). Conclusion In the in vitro mammalian cell gene mutation test dose range, no 90% mono-formamidine hydrochloride has mutagenicity.